NEW YORK (GenomeWeb) – 3D Signatures said today that it has signed a collaboration agreement with MDxHealth to evaluate Telo-PC, a test 3DS has developed for prostate cancer using its TeloView software platform.
Under the agreement the two companies will share the costs of conducting the study. 3DS has also granted MDxHealth an exclusive licensing option for the Telo-PC test.
"MDxHealth is constantly evaluating new opportunities that might allow us to increase our commercial footprint and we look forward to collaborating with 3DS to explore the potential of this partnership," MDxHealth CEO Jan Groen said in a statement.
According to the companies, the test could serve a "significant unmet need" for minimally invasive diagnostic and risk assessment tools that allow clinicians to make more informed treatment decisions for their prostate cancer patients.
3DS' technology involves three-dimensional analysis of the positioning of telomeres in a cell's nucleus, which the firm believes can allow the codification of signatures that correspond to disease stage, progression, and response to therapies in a variety of illnesses.
The company has been investigating use of the platform in prostate cancer in a clinical study called PRECISE.
"We hope this study [with MDxHealth] will continue to build on the evidence observed to date, which indicates that our Telo-PCTM test is able to predict the stability and aggressiveness of prostate cancer," 3DS CEO Jason Flowerday said in a statement.